Evommune, Inc. (EVMN)
Market Closed
16 Oct, 08:00 PM
NYSE NYSE Primary $
5. 17
-0.76
-12.8162%
$
215.21M Market Cap
- P/E Ratio
- Div Yield
986,400 Volume
- Eps
$ 5.93
Previous Close 
Want to track EVMN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
Zacks | 3 months ago
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Seekingalpha | 6 months ago
2026 © Marketlog. All Rights Reserved.
